Pharmacy News Article

6 October 2009 - Canadian specialty pharmaceutical company Biovail Corporation (TSE: BVF) today gave an update on the Phase III programe with pimavanserin for Parkinson's disease psychosis (PDP), which is being conducted in collaboration with US-based ACADIA Pharmaceuticals Inc (NASDAQ: ACAD).

Following the announcement on 1 September of disappointing top-line results from the first Phase III PDP trial, the two companies said they remain committed to the successful development of pimavanserin and have established a development strategy that they believe will strengthen the PDP programme. The parties also intend to pursue adjunctive therapy with pimavanserin for schizophrenia as a third indication in the collaboration.

ACADIA has conducted a substantial portion of the analysis of the data from its first Phase III PDP trial with pimavanserin (-012 Study). While the -012 Study did not meet its primary endpoint of antipsychotic efficacy and had a larger than expected placebo response, signals of antipsychotic efficacy were observed in the pimavanserin 40 mg study arm. These signals were most prominent in the United States portion of the study, which comprised nearly one-half of the patients in the trial. The efficacy signals also were supported by additional secondary and exploratory measures, including efficacy measures and favourable outcomes in assessments of sleep and caregiver burden. Several findings from the -012 Study will be used in the design of future PDP studies to help mitigate the placebo response and to increase the chances of success. These findings relate to dose selection, the method and application of ratings, and other study design elements.

The two companies have agreed on a development strategy for PDP that involves using the findings from the -012 Study together with those from the second, ongoing Phase III trial (-014 Study), which is testing 10 mg and 20 mg doses of pimavanserin, to arrive at an enhanced study design that may be used in new Phase III trials. Accordingly, the ongoing -014 Study will be concluded at its current enrollment level (about 120 patients) to allow for the analysis of data as soon as practicable. Meanwhile, the parties will begin planning for a new Phase III PDP trial using a 40 mg dose of pimavanserin. Consistent with the terms of the original collaboration agreement, Biovail will be responsible for the cost of this third Phase III trial. This study is expected to start in the first half of 2010. ACADIA will continue its ongoing open-label safety extension studies in patients with PDP.

In addition, Biovail intends to pursue adjunctive therapy with pimavanserin for schizophrenia as a third indication in the collaboration. Alzheimer's disease psychosis (ADP) remains the second indication provided for in the collaboration. The parties currently intend to focus their efforts on the PDP and schizophrenia programmes, but also are moving forward with planning for an initial study in ADP.

((Comments on this story may be sent to tww.feedback@m2.com))